It has been reported that BZYQT has anti-allergic properties through suppression of serum immunoglobulin E (IgE) levels and eosinophil infiltration, and controlling T-helper 1/T-helper 2 (Th1/Th2) balance.[13–17] Moreover, BZYQT also has immunomodulatory effects that prevent serum IgE level increase and correct the Th1/Th2 balance skewed to Th2 in atopic NC/Nga mice.[18,19] In addition, studies have reported on the protective effect of BZYQT against oxidative skin stress.[20] Likewise, many studies have been reported BZYQT to be effective in treating AD patients.[21–24]. The gene discussed is IGHE; the disease is Alzheimer disease.